Amfepramone-containing medicines will no longer be available on the EU market, as marketing authorisations will be revoked
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Active substance |
amfepramone
|
| Therapeutic area (MeSH) |
Obesity
|
| Procedure number |
EMEA/H/A-31/1501
|
| Regulatory outcome |
Revocation
|
| DHPC type |
Referral - Article 31
|
| Referral name |
Amfepramone-containing medicinal products
|
| Human ATC code |
A08AA03
|
| Dissemination date |
08/02/2023
|
| Related medicines |
|